Aclarion, Inc. (ACON) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Aclarion, Inc. is a healthcare technology company leveraging magnetic resonance spectroscopy (MRS) to optimize clinical treatments via its Nociscan reports. The company is classified as an emerging growth company and a smaller reporting company. As of May 11, 2026, there were 2,462,250 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $21,140 | $18,991 |
| Gross Profit | $3,750 | $(4,488) |
| Gross Margin | 17.7% | (23.6%) |
| Net Loss | $(2,853,575) | $(2,037,436) |
| Diluted EPS | $(1.34) | $(9.32) |
| Cash & Equivalents (End of Period) | $19,029,976 | $14,760,272 |
| Operating Cash Flow | $(2,641,845) | $(2,510,782) |
| Total Liabilities | $986,208 | $837,287 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 11.3% to $21,140, driven by growing volume of Nociscan reports in the UK market following local coverage decisions.
- Operating Expenses: Total operating expenses surged 101% to $2.99 million.
- Sales & Marketing: Increased 200% to $908,797 due to the initiation of the CLARITY clinical trial, expanded marketing consultants, and hiring.
- General & Administrative: Increased 79% to $1.77 million, primarily due to investor relations expenses ($360k vs $37k), legal fees, and a significant increase in Delaware franchise tax ($237k vs $9k).
- R&D: Increased 59% to $315,417, driven by higher patent maintenance fees.
- Non-Operating Items:
- Interest Income: Increased to $133,035 (from $42,163) due to higher cash balances.
- Penalties/Settlements: Decreased to $0 from $672,500 in Q1 2025 (which included a "fee tail" settlement).
- Liquidity: Cash position improved significantly due to a registered direct offering in January 2026 raising approximately $10.4 million in gross proceeds.
Outlook, Risks, and Unusual Items
- Capital Raise: In January 2026, the company completed a registered direct offering of common stock and pre-funded warrants. As of March 31, 2026, 1,362,500 pre-funded warrants had been exercised, with 437,500 remaining outstanding.
- Stockholder Rights Plan: On March 19, 2026, the board adopted a stockholder rights agreement (poison pill) to deter hostile takeovers. Rights expire March 18, 2027.
- Share Repurchase Program: In April 2026 (subsequent event), the board approved a $2.5 million share repurchase program.
- Liquidity Outlook: Management believes current cash resources ($19.0 million) are sufficient to fund operations for at least 12 months. However, the company expects operating expenses to increase as it advances commercialization and the CLARITY trial.
- Risks: The company faces risks typical of early-stage development, including limited operating history, dependence on key personnel, and the need for additional capital. There is no guarantee of success in addressing these risks.
Investor Verification Checklist
- Revenue Sustainability: Verify the durability of the 11% revenue growth and the timeline for additional insurance payor coverage in the UK and US.
- Burn Rate vs. Cash Runway: Confirm the 12-month liquidity runway given the 100%+ increase in operating expenses and the ongoing cash burn of ~$2.6M per quarter.
- CLARITY Trial Costs: Monitor the trajectory of Sales & Marketing expenses related to the CLARITY trial, which is expected to increase further in 2026.
- Delaware Franchise Tax: Investigate the methodology change causing the franchise tax to jump from $9k to $237k and its impact on future quarters.
- Dilution: Assess the impact of the 437,500 outstanding pre-funded warrants and the new $2.5M share repurchase program on share count and price.